LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
Poly (ADP-ribose) polymerase inhibitors (PARPis) are becoming increasingly meaningful in oncology, and their therapeutic drug monitoring (TDM) might be beneficial for patients. Several bioanalytical methods have been reported for PARPis quantification in human plasma, but advantages might be obtaine...
Saved in:
Main Authors: | Giovanni Canil (Author), Marco Orleni (Author), Bianca Posocco (Author), Sara Gagno (Author), Alessia Bignucolo (Author), Marcella Montico (Author), Rossana Roncato (Author), Serena Corsetti (Author), Michele Bartoletti (Author), Giuseppe Toffoli (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib
by: Kai Zhu, et al.
Published: (2024) -
Method development and validation of cabozantinib by LC-MS/MS
by: Punna Venkateshwarlu, et al.
Published: (2022) -
Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
by: Attwa MW, et al.
Published: (2020) -
Development and validation of an LC-MS/MS method for tyrphostin A9
by: Lyndsey F. Meyer, et al.
Published: (2019) -
Development and validation of an LC-MS/MS method for pharmacokinetic study of lobetyolin in rats
by: Haitao Tian, et al.
Published: (2023)